The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
DiaMedica said it plans to launch the trial later in 2026
The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
